Abstract PR1, an HLA-A*0201 epitope shared by proteinase-3 (PR3) and elastase (ELA2) proteins, is expressed in normal neutrophils and overexpressed in myeloid leukemias. PR1-speciWc T cells have been linked to graft-versusleukemia (GVL) eVect. We hypothesized that lymphopenia induced by chemo-radiotherapy can enhance weak autoimmune responses to self-antigens such as PR1. We measured PR1-speciWc responses in 27 patients 30-120 days following allogeneic stem cell transplant (SCT) and correlated these with ELA2 and PR3 expression and minimal residual disease (MRD). Post-SCT 10/13 CML, 6/9 ALL, and 4/5 solid tumor patients had PR1 responses correlating with PR3 and ELA2 expression. At day 180 post-SCT, 8/8 CML patients with PR1 responses were BCR-ABL-negative compared with 2/5 BCR-ABL-positive patients (P = 0.025). In contrast, PR1 responses were detected in 2/4 MRDnegative compared with 4/5 MRD-positive ALL patients (P = 0.76). To assess whether the lymphopenic milieu also exaggerates weak T-cell responses in the autologous setting, we measured spontaneous induction of PR1 responses in 3 AML patients vaccinated with WT1-126 peptide following lymphodepletion. In addition to WT1-speciWc T cells, we detected PR1-speciWc T cells in 2 patients during hematopoietic recovery. Our Wndings suggest that lymphopenia induced by chemo-radiotherapy enhances weak autoimmune responses to self-antigens, which may result in GVL if the leukemia expresses the relevant self-antigen.
Introduction
Following allogeneic stem cell transplantation (SCT) profound lymphopenia reduces the activation threshold of antigen-speciWc T cells and promotes homeostatic proliferation. This allows donor-derived alloantigen and selfantigen-speciWc T-cell clones to participate in rapid and extensive antigen-driven T-cell expansions [1] [2] [3] [4] [5] and may predispose to allo-or autoimmunity [6] . Additionally, the homeostatic drive to lymphoproliferation following lymphopenia may facilitate and enhance T-cell proliferation to low-aYnity self-antigens and induce anti-tumor immunity [2, 7] . Leukemia-associated antigens (LAA) including PR1, an HLA-A*0201 epitope shared by proteinase 3 (PR3) and elastase (ELA2) proteins, are self-antigens that induce low-frequency autoreactive T cells in patients with myeloid malignancies and healthy controls [8] [9] [10] [11] [12] [13] . PR3 and ELA2 are expressed in normal neutrophils and overexpressed in myeloid (but not lymphoid) leukemias [14] [15] [16] . We hypothesized that PR1 derived from recipient or donor myeloid cells might drive PR1-speciWc CD8+ T-cell expansion in the lymphopenic period early after allogeneic transplantation, leading to an eVective GVL response in patients with malignancies expressing PR3 and ELA2 antigens. To investigate whether the lymphopenic milieu could also facilitate the expansion of weak autoreactive T cells in the autologous setting, we developed a clinical trial of lymphodepletion by chemotherapy followed by the infusion of autologous lymphocytes and WT1 vaccination. The aim was to assess whether, in addition to WT1-speciWc T cells, we could also detect the induction of weak autoimmune responses to other normal self-antigens such as PR1. The rationale for infusing autologous lymphocytes at day ¡1 before vaccination was to further exploit the stimulatory cytokine milieu induced by severe lymphopenia (e.g., free interleukin-15 , IL-7) that may drive homeostatic lymphocyte expansion and to promote immune responses to weak leukemia-associated self-antigen vaccines.
Materials and methods

Patients and healthy controls
All donors and patients were treated at the National Institutes of Health (NIH) on protocols approved by the NIH Institutional Review Board. After informed consent, cells from patients with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and solid tumor were obtained from leukapheresis products (LPs) before stem cell transplantation. The cells were separated using FicollHypaque density gradient centrifugation (Organon Teknika, Durham, NC) and subsequently frozen in RPMI 1640 complete medium (CM) (Life Technologies, Gaithersburg, MD) supplemented with 20% heat-inactivated fetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO). Cells were thawed, washed, and suspended in RPMI-CM+ 10% pooled AB serum (Sigma Chemical, St Louis, MO). Highresolution HLA class I genotyping was performed by sequence-speciWc PCR using genomic DNA (HLA Laboratory, Department of Transfusion Medicine, Warren G. Magnusson Center, NIH, Bethesda, MD).
Transplantation approach
All patients with CML and ALL underwent a T celldepleted granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cell transplantation from their human leukocyte antigen (HLA)-identical sibling. The conditioning regimen was 12-Gy total body irradiation, Xudarabine (125 mg/m 2 ), and cyclophosphamide (Cy, 120 mg/kg). Donor CD34+ cells were positively selected using anti-CD34 beads (Isolex 300i immunomagnetic cell selection system, Nexell Therapeutics, Irvine, CA), and residual T cells were removed with a cocktail of anti-CD2, anti-CD6, and anti-CD7 antibody-coated beads (a kind gift from Dr Ronald Gress, National Cancer Institute, NIH, Bethesda, MD). The T-cell dose was Wxed at 2 £ 10 4 CD3+ T cells/kg recipient weight by adding back lymphocytes to the stem cell fraction where necessary. Patients received a low-dose cyclosporine A (CSA) (target plasma level 100-200 g/mL), starting on day ¡4. In the absence of acute GVHD, donor T cells (10 7 /kg) were added back preemptively on days 45-100 after transplantation. Patients with solid tumor received nonmyeloablative conditioning with cyclophosphamide (120 mg/kg) and Xudarabine (125 mg/ m 2 ) followed by the infusion of a G-CSF-mobilized hematopoietic cell allograft from an HLA-identical sibling. CSA alone or combined with mycophenolate mofetil or methotrexate was used as GVHD prophylaxis [17] .
Determination of donor-recipient chimerism after SCT
A quantitative PCR-based analysis of short tandem repeats was used to measure the donor-recipient chimerism separately in lymphoid and myeloid lineages as described previously [18] .
Peptide synthesis
Peptides used in this study were prepared by Biosynthesis (Lewisville, TX) to a minimum purity of 95%. The following peptides were tested: PR1 169-177 (VLQELNVTV), derived from the azurophilic granule proteins PR3 and ELA2 [8, 9] , WT1 126-134 (RMFPNAPYL) [19] [20] [21] , and CMV pp65 495-503 (NLVPMVATV) [22] .
Clinical vaccine trial
The primary objective of this phase I/II study was to evaluate the safety and eYcacy associated with an immunotherapy approach of lymphodepletion, followed by the infusion of autologous lymphocytes and WT1 vaccination (9 weekly doses of WT1:126-134 peptide in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim) in HLA-A*0201+ patients with refractory anemia with excess of blasts (MDS-RAEB) or in transformation (MDSRAEBt) and relapsed or refractory acute myeloid leukemia (AML). Safety and immunogenicity were the primary endpoints (NIH study #07-H-0091), ClinicalTrials.gov IdentiWer: NCT00433745. Other entry criteria included age 18-85 years, unsuitable for allogeneic stem cell transplantation (allo-SCT), and no corticosteroid treatment within 14 days prior to enrollment. The study was approved by the Institutional Review Board of the National Heart Lung Blood Institute (NHLBI). Following written informed consent, patients underwent a leukapheresis and the lymphocytes were cryopreserved for subsequent lymphocyte infusion.
Subjects then received Xudarabine 30 mg/m 2 iv on days ¡3 to ¡1 (total dose 90 mg/m 2 ) followed by the infusion of 1 £ 10 6 /kg of autologous cryopreserved lymphocytes (day ¡1), prior to vaccination. Starting on day 0, all subjects received subcutaneous injections of WT1 peptide (0.2 mg) in Montanide adjuvant (Seppic, Inc., FairWeld, NJ), weekly for 9 weeks. GM-CSF (100 g) (Sargramostim, Berlex Laboratories Inc., Richmond, California) was administered subcutaneously in the same region as the vaccine dose. Notably all subjects were lymphopenic at the time of the Wrst vaccination. Following vaccination, patients were reviewed weekly as outpatient for 16 weeks.
Vaccine preparation and administration WT1:126-134 (RMFPNAPYL) peptides was synthesized to GMP-grade by NeoMPS, Inc. (San Diego, California). The Pharmaceutical Development Section of the Pharmacy Department (NIH Clinical Center) reconstituted and vialed the peptide and provided quality assurance, IND#12632 [23] . The peptide was stored in dimethyl sulfoxide (DMSO) at ¡70°C and thawed on the day of injection. A water-in-oil emulsion vaccine was then prepared, consisting of the peptide (aqueous phase) and the adjuvant Montanide ® ISA-51 VG (oil phase), by combining equal parts of peptide and adjuvant. The emulsions formed were shown to be stable for at least 3 h.
Assessment of toxicity
At each outpatient visit, patients were evaluated for toxicities according to the National Cancer Institute Common Toxicity Criteria and independently reviewed by the Data Safety Monitoring Board.
Flow cytometric detection of functional antigen-speciWc CD8+ T cells Intracellular cytokine detection was performed as described previously [24] . In brief, peripheral blood mononuclear cells (PBMCs) (10 6 ) were loaded with or without test peptides (0.1 and 10 M). The response to CMV pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] was used as positive control. After 2 h, 10 g/mL Brefeldin A (Sigma, St Louis, MO) was added. After an additional 4 h, CD3+ CD8+ T cells were stained with an anti-CD3 peridinin chlorophyll protein (PerCP)-conjugated antibody and anti-CD8 phycoerythrin (PE)-conjugated antibody, Wxed/permeabilized, and then stained with an anti-interferon (IFN)-Xuorescein isothiocyanate (FITC) conjugate (all BD Pharmingen, San Jose, CA). A response was considered positive if the percentage of peptide-speciWc IFN--producing CD8+ T cells was twofold or higher compared with the percentage of IFN--producing CD8+ T cells in the absence of peptide and if there was a minimum of 0.05% peptide-speciWc IFN--producing CD8+ T cells [25] .
Peptide-HLA class I tetrameric staining Peripheral blood mononuclear cells (PBMCs) were stained with allophycocyanin (APC)-conjugated PR1/HLA-A*0201 (Beckman Coulter, Fullerton, CA), CMVpp65 495 / HLA-A*0201 (Beckman Coulter) and WT1/HLA-A*0201 tetramers (NIH tetramer facility) [23, 24] . Sample staining was performed using 1 £ 10 6 PBMCs in 50 L 1% fetal calf serum/phosphate-buVered saline (FCS/PBS). Tetramers were added for 20-30 min at 37°C. Cells were washed once in 1% FCS/PBS and then stained with a titrated panel of directly conjugated antibodies to CD3 and CD8 (Beckman Coulter, Miami, FL). FITC, PE, and PerCP were used as Xuorophores. The lymphocytes were then washed in 1% BSA in PBS and resuspended in 1% paraformaldehyde in PBS. A minimum of 0.5 £ 10 6 gated cells were acquired. Flow cytometry was performed on an LSR II Xow cytometer (BD Biosciences, San Jose, CA) using FacsDiva software (BD Biosciences).
Measurement of WT1, PR3, ELA2, and BCR-ABL by real-time quantitative reverse-transcription polymerase chain reaction (RQ-PCR)
All samples for RQ-PCR were blinded. RNA was isolated from a minimum of 10 6 PBMCs using RNeasy mini kits (Qiagen, Valencia, CA). cDNA was synthesized using the Advantage RT-for-PCR kit (Clontech, Mountain View, CA). TaqMan™ Gene Expression Assays (Applied Biosystems, Foster City, CA) for ELA2, Hs00357734_m1 and PR3, Hs00160521_m1 were utilized according to the manufacturer's instructions. Primers and probes for BCR-ABL, WT1, and ABL as the endogenous cDNA quantity control for all samples have been previously described [25] . Both WT1 and BCR-ABL RQ-PCR could consistently detect 1 leukemic cell in 1,000,000 nonleukemic cells [21] . All reactions were performed in triplicate on 10-L volume using standard conditions on the ABI PRISM 7,900 sequence detection system (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Data were analyzed by Fisher's exact test for categorical data and Mann-Whitney test for continuous data with the use of SPSS 17 for Windows software (SPSS, Chicago, IL) and Prism 4.00 for Windows software (GraphPad Software, San Diego, CA). P values were from 2-sided tests, with values <0.05 considered statistically signiWcant.
Results
PR1-speciWc CD8+ T cells are detectable early following allogeneic stem cell transplantation in patients receiving transplants for malignant diseases
Unstimulated PBMC samples from 27 HLA-A*0201-positive patients (13 CML, 9 ALL, and 5 solid tumor) in the Wrst 30-120 days following SCT were analyzed directly ex vivo for circulating CD8+ T cells speciWc for PR1 using PR1/HLA-A2 tetramer FACS staining. Clinical data are given in Table 1 . A CD8+ T-cell response to PR1 was observed in 10 of 13 patients with CML after SCT, with frequencies between 0 and 1.72%, median 0.18% of the CD8+ T-cell subpopulation (Table 2) . PR1-speciWc CD8+ T cells could also be detected in 10 of 14 recipients with nonmyeloid malignancies (6/9 ALL and 4/5 solid tumor patients) in the Wrst 30-120 days following T-cell-depleted SCT (Fig. 1a) . Interestingly in all patients, PR1-speciWc CD8+ T-cell responses were detected predominantly in the Wrst 30-120 days post-SCT. We next analyzed CD8+ T-cell responses to PR1 by intracellular IFN-staining in 13 patients in whom suYcient material for intracellular cytokine assay was available. CD8+ T cells speciWcally producing IFN-when exposed to PR1 were detected in 7 of 13 tested patients at frequencies between 0 and 1.77% of CD8+ T cells. These IFN-responders (patients 1, 2, 5, 7, 10, 11, and 16) also had CD8+ T-cell responses to PR1 detected by PR1/HLA-*0201 tetramer staining, whereas nonresponders (patients 4, 12, 13, and 22) were also negative for PR1 speciWcity by tetramer (Fig. 1b) . In samples from 2 patients (patients 3 and 8), no PR1-speciWc CD8+ T-cell responses could be detected by intracellular IFN-, whereas low-frequency responses were detected by PR1/HLA-A*0201 staining. In all patients, the frequencies of PR1-and CMV-speciWc CD8+ T cells detected by peptide/HLA-A2 tetramer staining were consistently greater than those detected by intracellular IFN-staining (Fig. 1b) . It is expected that intracellular IFN-assay following antigen stimulation under-estimates the frequencies of antigen-speciWc CD8+ T cells as subsets of tetramer-staining cells are likely to secrete other cytokines, such as TNF-, IL-2, or MIP-1 [26] , not tested in this study due to the sample limitations.
PR1-speciWc CD8+ T-cell responses correlate with ELA2 and PR3 expression
There was a highly signiWcant correlation between PR3 and ELA2 expression, r = 0.897, P < 0.0001 (Fig. 2a) (Fig. 2b) . In all patients, the emergence of PR1-speciWc T cells correlated with ELA2 expression levels (Since the expression of PR3 and ELA2 are highly correlated, only data on ELA2 expression are presented) (Fig. 3) . PR1/HLA-A*0201+ CD8+ T-cell emergence (light blue line) coincided with an increase in ELA2 gene expression (dark blue line). Similarly, loss of PR1/HLA-A*0201+ CD8+ T-cell responses correlated with a reduction in ELA2 gene expression. The time courses of the PR1 response and ELA2 gene expression in 6 representative patients are shown in Fig. 3 . PR3 and ELA2 are expressed in normal neutrophils and overexpressed in myeloid leukemias (but not lymphoid leukemias or solid tumors). Therefore, the source of PR1 antigen in patients with CML could be from leukemic or normal myeloid cells, whereas in ALL and solid tumor patients, PR1 antigen could only be derived from the rapidly eliminated normal recipient myeloid cells or from donor-derived regenerating normal myeloid cells. Chimerism analysis conWrmed that by day 30 post-SCT in all evaluable patients, the myeloid compartment was donorderived ( Table 1) ; suggesting that at least after day 30, PR3 and ELA2 expression could be directly related to donorderived myeloid reconstitution.
PR1-speciWc T-cell responses are associated with a GVL response in CML but not ALL
To determine the functional avidity of the PR1 T-cell response, the response of CD8+ T cells to stimulation with 2 concentrations of peptide (0.1 and 10 M) was measured by IC-IFN-staining. We deWned high-avidity CD8+ T cells as those capable of producing IFN-in response to a lower concentration of peptide (0.1 M), while low-avidity CD8+ T cells were those that produced IFN-in response to a higher concentration of peptide (10 M). We had IC-IFN-data for both peptide doses in 10 subjects. We determined the ratio of high-to low-avidity CD8+ T-cell responses. Ratios were obtained by the following calculation: (frequencies of IFN-+ CD8+ T cells with 0.1 M peptide)/(frequencies of IFN-+ CD8+ T cells with 10 M peptide). An arbitrary "functional avidity ratio" was thereby calculated. A ratio >1.0 was taken to represent predominantly high-avidity responses, whereas a ratio of <1.0 represents predominantly lowavidity responses. Both high-and low-avidity CD8+ T-cell responses could be detected in patients with CML and ALL (median high-/low-avidity ratio 1.1 and 1.1, respectively), P = 0.46 (Fig. 4a) , suggesting that the quality of the PR1-speciWc CD8+ T-cell response is not [21] , PR1 responses were detected in 2/4 patients who were MRD negative compared with 4/5 patients who were MRD positive on day 180 (P = 0.76) (Fig. 4b) . Therefore, it appears that if a self-antigen is shared by the leukemia cell and normal cell, a T-cell response can be induced irrespective of the source of antigen; however, a GVL response is only seen if the LAA is expressed by the leukemia cell.
Immune reconstitution following vaccination in patients with AML made lymphopenic and reconstituted with autologous PBMC We subsequently initiated a clinical trial in patients with high-risk MDS or relapsed AML to assess whether lymphodepletion followed by vaccination during lymphoid homeostasis can exaggerate weak immune responses and induce 'autoimmunity' against leukemia-associated selfantigens. Patients received weekly vaccination with the self-antigen WT1-126 peptide admixed with Montanide adjuvant plus GM-CSF following an immunotherapy approach of lymphodepletion by chemotherapy and infusion of previously harvested autologous lymphocytes. Four patients with relapsed AML following induction chemotherapy were enrolled, 1 man and 3 women, median age 55 years (range 45-73 years). Notably, none of these patients had been enrolled on PR1 or WT1 peptide vaccine study previously [23, 27] . One patient progressed before the start of treatment and was withdrawn from the study. Three patients completed the study protocol including preparative chemotherapy, reconstitution of autologous PBMC, vaccination and post-vaccination immune monitoring to week 16.
Fresh PBMC collected pre-and 2-weekly post-vaccination and on week 16 were analyzed directly ex vivo by Xow cytometry for circulating WT1-speciWc CD8+ T cells. To test the hypothesis that lymphopenia can promote homeostatic proliferation against other weak self-antigens, we also looked for the presence of PR1-speciWc CD8+ T cells by PR1/HLA-A2 tetramer staining and IC-IFN-gamma assay [23, 24] . None of the patients had WT1-or PR1-speciWc CD8+ T cells prior to vaccination. Two of 3 patients had detectable WT1-speciWc CD8+ T cells following vaccination (Fig. 5) . Vaccine-induced CD8+ T cells were detected as early as 2 weeks following the Wrst dose of vaccine. Interestingly, PR1-speciWc CD8+ T cells were also detected in 2 of 3 patients during hematopoietic recovery (Fig. 5) . These data support the concept of an 'auto-vaccination' process and suggest that the lymphopenic milieu is favorable for exaggerating weak autoimmune responses to normal self-antigens such as PR1.
Discussion
In this study, we show that increased T-cell responses to a self-antigen, PR1, are a common occurrence in the early post-transplant period and after lymphodepleting chemotherapy. Since these responses are also seen in transplants where the only source of PR1 antigen is from the rapidly eliminated recipient marrow or the incoming donor marrow, it appears that at least in the Wrst few weeks after SCT, [28, 29] , the process of hematopoietic recovery may also make elastase-or proteinase-3-derived PR1 available for immune recognition. This dual mechanism is likely to also apply in the autologous setting and is supported by our observation that both PR1 and vaccine-induced WT1-speciWc T cells emerge following lymphodepletion and myelosuppressive chemotherapy in the WT1 vaccine study. These data are further supported by recent reports that the eYcacy of chemotherapy could be at least partly mediated through an immune eVect, either directly via the stimulation of anticancer immune eVectors [30] or by subverting immunosuppressive mechanisms such as immune inhibitory pathways [31] . The origin of the increased elastase levels we detected is not well deWned but the timing and the comparable changes in the PR1-speciWc T cells in the vaccine study suggest that elastase is made available to APC either as a consequence of cell death following chemotherapy or as a consequence of hematopoietic recovery. Therefore, it appears that lymphodepletion following SCT or chemotherapy supports the induction of an 'auto-vaccination' process. The implications of our Wndings are threefold. Firstly, they suggest that despite the administration of a calcineurin inhibitor as prophylaxis against GVHD, the early period post-transplant may present opportunities for vaccination to further boost this "anamnestic" T-cell response to leukemia antigens. These results are in keeping with previous reports that lymphopenia induces changes in immune physiology that exaggerate weak immune responses and that result in T-cell proliferation toward self-antigens [32] [33] [34] [35] . Therefore, the immediate period of lymphopenia post-cytoreduction may provide a unique opportunity for eVective antitumor immunotherapy. A number of studies in multiple myeloma and AML incorporated vaccination in the posttransplant setting (autologous or allogeneic) [36] [37] [38] [39] . While immunological responses could be detected, convincing clinical responses were absent. Notably, these studies administered the vaccines months following transplantation, after exponential T-cell proliferation has likely occurred. In a recent phase 1 trial, Ho and colleagues vaccinated patients with high-risk MDS and AML with lethally irradiated, autologous, GM-CSF-secreting leukemia cells early after allogeneic SCT. They reported that, despite the use of the calcineurin inhibitor tacrolimus as GVHD prophylaxis, immunization in this setting was safe, immunogenic, and associated with biological activity [40] . Further studies will determine whether vaccination during lymphopenia-driven homeostasis can actually lead to signiWcant clinical responses.
Secondly, it appears that in the case of a nonmutated leukemia-associated antigen expressed by both normal cells and leukemia, either antigenic source can drive the expansion of weak immune responses against the shared self-antigen during homeostatic proliferation. Indeed in our study, PR1-speciWc T-cell responses were not CML-restricted and were also seen in patients with ALL and solid tumor early following SCT. Furthermore, PR1-speciWc T-cell responses were of similar magnitude and quality (in terms of avidity) in patients with CML, ALL, and solid tumor. PR3 and ELA2 are expressed in normal neutrophils and overexpressed in myeloid leukemias but not in lymphoid malignancies or solid tumors. Whereas the source of PR1 antigen in CML could be from apoptotic leukemia cells or from necrotic normal myeloid cells following conditioning, in patients with ALL and solid tumor, the PR1-speciWc CD8+ T-cell response could only be driven by the increased PR3 or ELA2 released from the rapidly eliminated apoptotic normal recipient myeloid compartment or by donor myelopoiesis. We then analyzed the ability of PR1-speciWc CD8+ T cells detected by tetramer staining and intracellular IFNproduction to mediate in vivo anti-leukemic cytotoxicity by correlating the emergence of PR1-speciWc CD8 + T cells with MRD in the peripheral blood at day +180 post-SCT. In patients with CML, the presence of PR1-speciWc CD8 + T cells was associated with MRD negativity as assessed by BCR-ABL expression, whereas using WT1 gene expression as a surrogate marker of MRD [21, [41] [42] [43] [44] , we found no association between PR1 T-cell responses in patients with ALL and WT1 levels post-SCT. Therefore, it appears that an association between PR1-speciWc CD8+ T-cell responses post-SCT and GVL is only seen if the leukemia cell expresses the LAA as in CML, but not if the leukemia does not express the shared antigen, as with ALL or solid tumor. It is interesting that expansion of PR1-speciWc CD8+ T cells is not associated with neutropenia post-SCT (Fig. 3) . Proteinase 3 and elastase are overexpressed in myeloid leukemia cells compared with normal myeloid progenitors [14] [15] [16] , and the speciWc lysis of myeloid leukemia cells by PR1-speciWc CTL correlates with aberrant expression of proteinase 3 in target cells [8] . Furthermore, a recent study reported that an anti-PR1/HLA-A2 T-cell receptor-like antibody can preferentially inhibit leukemia progenitors over normal hematopoietic progenitors [42] . It is probable that early post-SCT, PR1-speciWc CD8+ T cells do not target normal myeloid progenitors expressing lower surface expression of proteinase 3, whereas the higher expression of proteinase 3 on CML progenitors might be suYcient to cause recognition and killing by lower-avidity PR1-CTL, although in this study we could not demonstrate a relationship between PR3 or ELA2 expression and MRD status (data not shown).
Thirdly, studying the immune milieu post-transplant can help deWne the factors permissive to antigen-speciWc T-cell expansion, which could in turn lead to improved ways to boost T-cell responses to vaccine and immunotherapy. Recent evidence suggests that IL-7 [45, 46] and IL-15 act as homeostatic cytokines, supporting homeostatic peripheral expansion in lymphopenic hosts [1, [47] [48] [49] . Furthermore, our group and others have shown that following lymphodepletion, the frequencies of Tregs are initially low but rise rapidly to normal or supra-normal levels, suggesting that the permissive period for antigen-driven T-cell expansion is brief [28, 29, 50, 51] . These factors may partly explain our previous observation that whereas vaccination with one dose of PR1 and WT1 peptides induces transient anti-leukemia immunity, repeated vaccination with these peptide vaccines fails to induce sustained immune responses [23] .
In summary, our results suggest that the vigorous homeostatic proliferation of donor T cells after allogeneic SCT, especially in a T-depleted setting, or following chemotherapy, may represent a hitherto under-utilized window of opportunity for immunotherapy. To maximize the suc- 
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cess of immunotherapy and the promising results seen to date in vaccination trials using self-antigens [23, 27, [52] [53] [54] [55] [56] [57] , future studies may alter the donor graft to skew the initial homeostatic T-cell expansion toward LAA, either by vaccinating the donor with LAA or by infusing genetically engineered or ex vivo expanded LAA-speciWc T cells together with the graft. Vaccines could then be introduced in the lymphopenic phase after SCT to capture the proliferative boost induced by excess cytokine production, and before the recovery of regulatory T cells. An improved understanding of the cytokine and cellular inXuences that contribute to the generation of antigen-speciWc T cells during lymphopenia-driven homeostasis may have important implications for the development of more directed, less toxic approaches for enhancing the eVectiveness of immunotherapy in the clinic. 
